![Christopher Ehrlich](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christopher Ehrlich
Founder at Prostate Management Diagnostics, Inc.
Net worth: 450 910 $ as of 2024-05-30
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Brian Atwood | M | 71 | 3 years | |
Douglas Fisher | M | 48 |
Prostate Management Diagnostics, Inc.
![]() Prostate Management Diagnostics, Inc. BiotechnologyHealth Technology Prostate Management Diagnostics, Inc. engages in the provision of research and test of fluid-based screening tool to identify patients at risk of prostate cancer. It performs research on a series of genetic markers that could determine whether a prostrate cancer is indolent or aggressive in patients newly diagnosed with the disease. The company was founded by Christopher B. Ehrlich and Douglas C. Fisher in 2014 and is headquartered in Sausalito, CA.
InterWest Partners LLC
![]() InterWest Partners LLC Investment ManagersFinance InterWest Partners LLC (InterWest Partners) is a venture capital firm founded in 1979 by Wally Hawley, Scott Hedrick and Gene Barth. The firm is headquartered in San Francisco, California. | 15 years |
Michael Byrnes | M | 47 | 4 years | |
Kathy LaPorte | F | 62 |
Transcept Pharma, Inc.
![]() Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | 7 years |
Daniel V. Santi | M | 82 |
Prolynx LLC
![]() Prolynx LLC Miscellaneous Commercial ServicesCommercial Services Prolynx LLC engages in the development of proprietary drug delivery system for half-life extension of proteins, peptides, and small molecules. Its pipeline includes PLX038, PEG-PARP, IL-15, IL-2, PTH 1-34, GLP-1RA, and QMo IVT. The company was founded by Daniel V. Santi and Gary W. Ashley in 2010 and is headquartered in San Francisco, CA. | 14 years |
Gary W. Ashley | M | - |
Prolynx LLC
![]() Prolynx LLC Miscellaneous Commercial ServicesCommercial Services Prolynx LLC engages in the development of proprietary drug delivery system for half-life extension of proteins, peptides, and small molecules. Its pipeline includes PLX038, PEG-PARP, IL-15, IL-2, PTH 1-34, GLP-1RA, and QMo IVT. The company was founded by Daniel V. Santi and Gary W. Ashley in 2010 and is headquartered in San Francisco, CA. | 14 years |
Daniel Corey | M | 44 | 3 years | |
Lindsey Rolfe | M | 56 | - | |
Walter Menzel | M | 77 |
Prostate Management Diagnostics, Inc.
![]() Prostate Management Diagnostics, Inc. BiotechnologyHealth Technology Prostate Management Diagnostics, Inc. engages in the provision of research and test of fluid-based screening tool to identify patients at risk of prostate cancer. It performs research on a series of genetic markers that could determine whether a prostrate cancer is indolent or aggressive in patients newly diagnosed with the disease. The company was founded by Christopher B. Ehrlich and Douglas C. Fisher in 2014 and is headquartered in Sausalito, CA. | - |
Charles Carter | M | 57 | - | |
Richard A. King | M | 59 |
Prolynx LLC
![]() Prolynx LLC Miscellaneous Commercial ServicesCommercial Services Prolynx LLC engages in the development of proprietary drug delivery system for half-life extension of proteins, peptides, and small molecules. Its pipeline includes PLX038, PEG-PARP, IL-15, IL-2, PTH 1-34, GLP-1RA, and QMo IVT. The company was founded by Daniel V. Santi and Gary W. Ashley in 2010 and is headquartered in San Francisco, CA. | 2 years |
Stuart L. Dombey | M | - |
QuatRx Pharmaceuticals Co.
![]() QuatRx Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology QuatRx Pharmaceuticals Co. manufactures and develops therapeutic compounds. Its clinical products, ospemifene and fispemifene, treat hormone deficiencies that result from aging in women and men. The firm's preclinical program is designed to address sex steroid dependent diseases through inhibition of 17beta- hydroxysteroid dehydrogenase (HSD) enzymes. The company was founded by Robert Zerbe, Christopher Nicholas, and Stuart Dombey on November 20 2000 and is headquartered in Ann Arbor, MI. | 24 years |
Khaled Asad Nasr | M | 66 |
InterWest Partners LLC
![]() InterWest Partners LLC Investment ManagersFinance InterWest Partners LLC (InterWest Partners) is a venture capital firm founded in 1979 by Wally Hawley, Scott Hedrick and Gene Barth. The firm is headquartered in San Francisco, California. | 19 years |
Robyn Rapaport | F | 31 | - | |
Charline Gauthier | M | 61 |
InterWest Partners LLC
![]() InterWest Partners LLC Investment ManagersFinance InterWest Partners LLC (InterWest Partners) is a venture capital firm founded in 1979 by Wally Hawley, Scott Hedrick and Gene Barth. The firm is headquartered in San Francisco, California. | 16 years |
Mayank J. Gandhi | M | 47 | 2 years | |
Keval Desai | M | - |
InterWest Partners LLC
![]() InterWest Partners LLC Investment ManagersFinance InterWest Partners LLC (InterWest Partners) is a venture capital firm founded in 1979 by Wally Hawley, Scott Hedrick and Gene Barth. The firm is headquartered in San Francisco, California. | 13 years |
Anurag Bagaria | M | 47 |
Prolynx LLC
![]() Prolynx LLC Miscellaneous Commercial ServicesCommercial Services Prolynx LLC engages in the development of proprietary drug delivery system for half-life extension of proteins, peptides, and small molecules. Its pipeline includes PLX038, PEG-PARP, IL-15, IL-2, PTH 1-34, GLP-1RA, and QMo IVT. The company was founded by Daniel V. Santi and Gary W. Ashley in 2010 and is headquartered in San Francisco, CA. | - |
Charlie Bolten | M | - |
Prostate Management Diagnostics, Inc.
![]() Prostate Management Diagnostics, Inc. BiotechnologyHealth Technology Prostate Management Diagnostics, Inc. engages in the provision of research and test of fluid-based screening tool to identify patients at risk of prostate cancer. It performs research on a series of genetic markers that could determine whether a prostrate cancer is indolent or aggressive in patients newly diagnosed with the disease. The company was founded by Christopher B. Ehrlich and Douglas C. Fisher in 2014 and is headquartered in Sausalito, CA. | - |
Mark G. Edwards | M | 66 |
Prolynx LLC
![]() Prolynx LLC Miscellaneous Commercial ServicesCommercial Services Prolynx LLC engages in the development of proprietary drug delivery system for half-life extension of proteins, peptides, and small molecules. Its pipeline includes PLX038, PEG-PARP, IL-15, IL-2, PTH 1-34, GLP-1RA, and QMo IVT. The company was founded by Daniel V. Santi and Gary W. Ashley in 2010 and is headquartered in San Francisco, CA. | 5 years |
Gary Onn | M | - |
QuatRx Pharmaceuticals Co.
![]() QuatRx Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology QuatRx Pharmaceuticals Co. manufactures and develops therapeutic compounds. Its clinical products, ospemifene and fispemifene, treat hormone deficiencies that result from aging in women and men. The firm's preclinical program is designed to address sex steroid dependent diseases through inhibition of 17beta- hydroxysteroid dehydrogenase (HSD) enzymes. The company was founded by Robert Zerbe, Christopher Nicholas, and Stuart Dombey on November 20 2000 and is headquartered in Ann Arbor, MI. | - |
Sérgio Tavares Rebelo | M | 64 |
Kellogg School of Management
| 27 years |
Michael S. Rabson | M | 70 |
Prolynx LLC
![]() Prolynx LLC Miscellaneous Commercial ServicesCommercial Services Prolynx LLC engages in the development of proprietary drug delivery system for half-life extension of proteins, peptides, and small molecules. Its pipeline includes PLX038, PEG-PARP, IL-15, IL-2, PTH 1-34, GLP-1RA, and QMo IVT. The company was founded by Daniel V. Santi and Gary W. Ashley in 2010 and is headquartered in San Francisco, CA. | - |
Stephen Scott Rodde | M | - |
Prostate Management Diagnostics, Inc.
![]() Prostate Management Diagnostics, Inc. BiotechnologyHealth Technology Prostate Management Diagnostics, Inc. engages in the provision of research and test of fluid-based screening tool to identify patients at risk of prostate cancer. It performs research on a series of genetic markers that could determine whether a prostrate cancer is indolent or aggressive in patients newly diagnosed with the disease. The company was founded by Christopher B. Ehrlich and Douglas C. Fisher in 2014 and is headquartered in Sausalito, CA. | - |
William J. Rutter | M | - |
Prolynx LLC
![]() Prolynx LLC Miscellaneous Commercial ServicesCommercial Services Prolynx LLC engages in the development of proprietary drug delivery system for half-life extension of proteins, peptides, and small molecules. Its pipeline includes PLX038, PEG-PARP, IL-15, IL-2, PTH 1-34, GLP-1RA, and QMo IVT. The company was founded by Daniel V. Santi and Gary W. Ashley in 2010 and is headquartered in San Francisco, CA. | - |
Albert Luderer | M | 75 |
Prostate Management Diagnostics, Inc.
![]() Prostate Management Diagnostics, Inc. BiotechnologyHealth Technology Prostate Management Diagnostics, Inc. engages in the provision of research and test of fluid-based screening tool to identify patients at risk of prostate cancer. It performs research on a series of genetic markers that could determine whether a prostrate cancer is indolent or aggressive in patients newly diagnosed with the disease. The company was founded by Christopher B. Ehrlich and Douglas C. Fisher in 2014 and is headquartered in Sausalito, CA. | 8 years |
Richard Fox | M | 76 |
QuatRx Pharmaceuticals Co.
![]() QuatRx Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology QuatRx Pharmaceuticals Co. manufactures and develops therapeutic compounds. Its clinical products, ospemifene and fispemifene, treat hormone deficiencies that result from aging in women and men. The firm's preclinical program is designed to address sex steroid dependent diseases through inhibition of 17beta- hydroxysteroid dehydrogenase (HSD) enzymes. The company was founded by Robert Zerbe, Christopher Nicholas, and Stuart Dombey on November 20 2000 and is headquartered in Ann Arbor, MI. | 18 years |
Bora Han | M | - |
Prolynx LLC
![]() Prolynx LLC Miscellaneous Commercial ServicesCommercial Services Prolynx LLC engages in the development of proprietary drug delivery system for half-life extension of proteins, peptides, and small molecules. Its pipeline includes PLX038, PEG-PARP, IL-15, IL-2, PTH 1-34, GLP-1RA, and QMo IVT. The company was founded by Daniel V. Santi and Gary W. Ashley in 2010 and is headquartered in San Francisco, CA. | 4 years |
Anders Hove | M | 58 |
QuatRx Pharmaceuticals Co.
![]() QuatRx Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology QuatRx Pharmaceuticals Co. manufactures and develops therapeutic compounds. Its clinical products, ospemifene and fispemifene, treat hormone deficiencies that result from aging in women and men. The firm's preclinical program is designed to address sex steroid dependent diseases through inhibition of 17beta- hydroxysteroid dehydrogenase (HSD) enzymes. The company was founded by Robert Zerbe, Christopher Nicholas, and Stuart Dombey on November 20 2000 and is headquartered in Ann Arbor, MI. | 17 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Glenn A. Oclassen | M | 81 |
Transcept Pharma, Inc.
![]() Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | - |
Thomas Soloway | M | 55 |
Transcept Pharma, Inc.
![]() Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | 11 years |
Elizabeth Bhatt | F | 56 | 3 years | |
Caroline Loewy | F | 58 | 2 years | |
Robert Zerbe | M | 73 |
QuatRx Pharmaceuticals Co.
![]() QuatRx Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology QuatRx Pharmaceuticals Co. manufactures and develops therapeutic compounds. Its clinical products, ospemifene and fispemifene, treat hormone deficiencies that result from aging in women and men. The firm's preclinical program is designed to address sex steroid dependent diseases through inhibition of 17beta- hydroxysteroid dehydrogenase (HSD) enzymes. The company was founded by Robert Zerbe, Christopher Nicholas, and Stuart Dombey on November 20 2000 and is headquartered in Ann Arbor, MI. | 16 years |
G. Kirk Raab | M | 88 |
Transcept Pharma, Inc.
![]() Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | - |
John C. Adler | M | - |
InterWest Partners LLC
![]() InterWest Partners LLC Investment ManagersFinance InterWest Partners LLC (InterWest Partners) is a venture capital firm founded in 1979 by Wally Hawley, Scott Hedrick and Gene Barth. The firm is headquartered in San Francisco, California. | - |
Camille Samuels | F | 52 |
Transcept Pharma, Inc.
![]() Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA.
The Lek/Alcar Consulting Group, Inc.
![]() The Lek/Alcar Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Lek/Alcar Consulting Group, Inc. provides business strategy consulting services. It offers strategy, finance, marketing and sales, operations, and transaction services including business unit strategy, brand management, pricing, alliances and joint ventures, product development, corporate transformation, and operations design. It serves the defense, energy, health, building and construction, aerospace, media, retail, and telecommunications industries. The company was founded by Andrew Kutter in 1983 and is headquartered in Boston, MA. | 5 years |
Brian Gallagher | M | 54 | 4 years | |
Stephen Worland | M | 66 | 12 years | |
Gary E. Friedlaender | M | 78 |
BioMimetic Therapeutics, Inc.
![]() BioMimetic Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology BioMimetic Therapeutics, Inc. developed and sells protein therapeutics for tissue and organ regeneration. The company was founded by Samuel E. Lynch and David M. Renzi on April 14, 1999 and was headquartered in Franklin, TN. | - |
Frederick J. Ruegsegger | M | 68 |
Transcept Pharma, Inc.
![]() Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | - |
Jay Mohr | M | - |
Locust Walk Partners LLC
![]() Locust Walk Partners LLC Miscellaneous Commercial ServicesCommercial Services Locust Walk Partners LLC provides commercial supporting and advisory services. The firm involves in securities-related transactions for clients, including mergers and acquisitions, private placements & mezzanine financings and partnerships involving equity investments. The company was founded by Geoff Meyerson and Joseph Mohr in 2008 and is headquartered in Boston, MA. | 8 years |
Jon M. Haas | M | 52 |
Kellogg School of Management
Dartmouth College
| 7 years |
Mike D. Boich | M | - |
InterWest Partners LLC
![]() InterWest Partners LLC Investment ManagersFinance InterWest Partners LLC (InterWest Partners) is a venture capital firm founded in 1979 by Wally Hawley, Scott Hedrick and Gene Barth. The firm is headquartered in San Francisco, California. | 3 years |
Jon Root | M | 64 | 1 years | |
Shane McCarthy | M | - |
Kellogg School of Management
| 3 years |
Barbara Kosacz | F | 66 | - | |
Larry Lasky | M | 73 | - | |
Randall W. Whitcomb | M | 69 |
QuatRx Pharmaceuticals Co.
![]() QuatRx Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology QuatRx Pharmaceuticals Co. manufactures and develops therapeutic compounds. Its clinical products, ospemifene and fispemifene, treat hormone deficiencies that result from aging in women and men. The firm's preclinical program is designed to address sex steroid dependent diseases through inhibition of 17beta- hydroxysteroid dehydrogenase (HSD) enzymes. The company was founded by Robert Zerbe, Christopher Nicholas, and Stuart Dombey on November 20 2000 and is headquartered in Ann Arbor, MI. | 5 years |
John Smither | M | 71 | 2 years | |
Michelle Snyder | F | - |
InterWest Partners LLC
![]() InterWest Partners LLC Investment ManagersFinance InterWest Partners LLC (InterWest Partners) is a venture capital firm founded in 1979 by Wally Hawley, Scott Hedrick and Gene Barth. The firm is headquartered in San Francisco, California.
Kellogg School of Management
| 2 years |
Daniel Stephen Hafner | M | 56 |
Kellogg School of Management
Dartmouth College
| 7 years |
Barbara Klencke | M | 66 | 3 years | |
Leo Snel | M | - |
BioMimetic Therapeutics, Inc.
![]() BioMimetic Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology BioMimetic Therapeutics, Inc. developed and sells protein therapeutics for tissue and organ regeneration. The company was founded by Samuel E. Lynch and David M. Renzi on April 14, 1999 and was headquartered in Franklin, TN. | - |
Alana McNulty | F | 61 | 10 years | |
Will Price | M | - |
Kellogg School of Management
| 2 years |
Charles Federico | M | 75 |
BioMimetic Therapeutics, Inc.
![]() BioMimetic Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology BioMimetic Therapeutics, Inc. developed and sells protein therapeutics for tissue and organ regeneration. The company was founded by Samuel E. Lynch and David M. Renzi on April 14, 1999 and was headquartered in Franklin, TN. | - |
Linda Grais | M | 68 |
InterWest Partners LLC
![]() InterWest Partners LLC Investment ManagersFinance InterWest Partners LLC (InterWest Partners) is a venture capital firm founded in 1979 by Wally Hawley, Scott Hedrick and Gene Barth. The firm is headquartered in San Francisco, California. | 6 years |
Kristen Harrington-Smith | F | 51 | 2 years | |
Jake Nunn | M | 53 |
Transcept Pharma, Inc.
![]() Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | - |
Dan Turner | M | 62 |
Transcept Pharma, Inc.
![]() Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | 2 years |
James G. Murphy | M | 68 |
BioMimetic Therapeutics, Inc.
![]() BioMimetic Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology BioMimetic Therapeutics, Inc. developed and sells protein therapeutics for tissue and organ regeneration. The company was founded by Samuel E. Lynch and David M. Renzi on April 14, 1999 and was headquartered in Franklin, TN. | - |
Steven N. Hirsch | M | 72 |
BioMimetic Therapeutics, Inc.
![]() BioMimetic Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology BioMimetic Therapeutics, Inc. developed and sells protein therapeutics for tissue and organ regeneration. The company was founded by Samuel E. Lynch and David M. Renzi on April 14, 1999 and was headquartered in Franklin, TN. | 5 years |
Russell P. Pagano | M | 58 |
BioMimetic Therapeutics, Inc.
![]() BioMimetic Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology BioMimetic Therapeutics, Inc. developed and sells protein therapeutics for tissue and organ regeneration. The company was founded by Samuel E. Lynch and David M. Renzi on April 14, 1999 and was headquartered in Franklin, TN. | - |
Joseph T. Kennedy | M | 56 |
Transcept Pharma, Inc.
![]() Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | 2 years |
Thomas D. Kiley | M | 80 |
Transcept Pharma, Inc.
![]() Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | - |
W. Scott Hedrick | M | 78 |
InterWest Partners LLC
![]() InterWest Partners LLC Investment ManagersFinance InterWest Partners LLC (InterWest Partners) is a venture capital firm founded in 1979 by Wally Hawley, Scott Hedrick and Gene Barth. The firm is headquartered in San Francisco, California. | 29 years |
Matthew M. Loar | M | 61 |
Transcept Pharma, Inc.
![]() Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | - |
Marilyn E. Wortzman | F | 77 |
Transcept Pharma, Inc.
![]() Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | 3 years |
John Carroll | M | 56 |
Kellogg School of Management
Dartmouth College
| 7 years |
Patrick Heron | M | 53 |
QuatRx Pharmaceuticals Co.
![]() QuatRx Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology QuatRx Pharmaceuticals Co. manufactures and develops therapeutic compounds. Its clinical products, ospemifene and fispemifene, treat hormone deficiencies that result from aging in women and men. The firm's preclinical program is designed to address sex steroid dependent diseases through inhibition of 17beta- hydroxysteroid dehydrogenase (HSD) enzymes. The company was founded by Robert Zerbe, Christopher Nicholas, and Stuart Dombey on November 20 2000 and is headquartered in Ann Arbor, MI. | 17 years |
Thomas Dietz | M | 60 |
Transcept Pharma, Inc.
![]() Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | 1 years |
Keith Lenden | M | - |
Dartmouth College
| 4 years |
Thomas Salopek | M | - |
Dartmouth College
| 4 years |
Peter W. Chapman | M | - |
Dartmouth College
| 4 years |
Timothy G. Healy | M | - |
Dartmouth College
| 4 years |
Andrew Weinberg | M | 50 |
Dartmouth College
| 4 years |
Richard D. Manuel | M | - |
Dartmouth College
| 4 years |
Malik Franklin | M | 51 |
Dartmouth College
| 4 years |
Samantha Truex | F | - |
Dartmouth College
| 4 years |
Enrique Colbert | M | 50 |
Dartmouth College
| 4 years |
Aldo Pascarella | M | - |
Dartmouth College
| 4 years |
Jordan Green | M | - |
Dartmouth College
| 4 years |
Chi Lee | M | - |
Dartmouth College
| 4 years |
Sturgis Paul Woodberry | M | - |
Dartmouth College
| 4 years |
John Fredrick Barrett | M | 49 |
Dartmouth College
| 4 years |
Todd C. Marker | M | - |
Dartmouth College
| 3 years |
Douglas T. Sheehy | M | 57 |
Dartmouth College
| 4 years |
Trevor Burgess | M | 51 |
Dartmouth College
| 4 years |
Scott Wu | M | - |
Dartmouth College
| 4 years |
Ramiro Albarran | M | - |
Dartmouth College
| 4 years |
Eric Bjorkman | M | - |
Dartmouth College
| 4 years |
Robert P. Bennett | M | - |
Dartmouth College
| 5 years |
Lawrence P. Cook | M | - |
Dartmouth College
| 4 years |
David Gene-Ho Hyun | M | - |
Dartmouth College
| 4 years |
Jeff Cucunato | M | - |
Dartmouth College
| 4 years |
Holden Spaht | M | 49 |
Dartmouth College
| 4 years |
Robert Kendall McConnaughey | M | 54 |
Dartmouth College
| 4 years |
Kurt Duplan Rieke | M | - |
Dartmouth College
| 4 years |
Bruce Steel | M | 57 |
Dartmouth College
| 4 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 96 | 96.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Christopher Ehrlich
- Personal Network